Stereotaxis, Inc. (AMEX: STXS) Stock Competitors & Peer Comparison

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas SIRO's P/E ratio is 31.88. In terms of profitability, STXS's ROE is -1.53%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, STXS is more volatile compared to SIRO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check SIRO's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while HIMS trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas HIMS's P/E ratio is -315.90. In terms of profitability, STXS's ROE is -1.53%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, STXS is more volatile compared to HIMS. This indicates higher risk in terms of short-term price fluctuations for STXS.Check HIMS's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while MMED trades at $19.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas MMED's P/E ratio is -25.29. In terms of profitability, STXS's ROE is -1.53%, compared to MMED's ROE of -0.14%. Regarding short-term risk, STXS is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for STXS.Check MMED's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while OMCL trades at $36.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas OMCL's P/E ratio is 19.27. In terms of profitability, STXS's ROE is -1.53%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, STXS is more volatile compared to OMCL. This indicates higher risk in terms of short-term price fluctuations for STXS.Check OMCL's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while DRTS trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas DRTS's P/E ratio is -19.61. In terms of profitability, STXS's ROE is -1.53%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, STXS is more volatile compared to DRTS. This indicates higher risk in terms of short-term price fluctuations for STXS.Check DRTS's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while MLAB trades at $102.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas MLAB's P/E ratio is 10.36. In terms of profitability, STXS's ROE is -1.53%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, STXS is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for STXS.Check MLAB's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while LAB trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas LAB's P/E ratio is -11.43. In terms of profitability, STXS's ROE is -1.53%, compared to LAB's ROE of -0.18%. Regarding short-term risk, STXS is more volatile compared to LAB. This indicates higher risk in terms of short-term price fluctuations for STXS.Check LAB's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while FONR trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas FONR's P/E ratio is 19.09. In terms of profitability, STXS's ROE is -1.53%, compared to FONR's ROE of +0.04%. Regarding short-term risk, STXS is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check FONR's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while LNSR trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas LNSR's P/E ratio is 6.16. In terms of profitability, STXS's ROE is -1.53%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, STXS is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for STXS.Check LNSR's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas KDLY's P/E ratio is -15.48. In terms of profitability, STXS's ROE is -1.53%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, STXS is more volatile compared to KDLY. This indicates higher risk in terms of short-term price fluctuations for STXS.Check KDLY's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas NEUE's P/E ratio is -0.38. In terms of profitability, STXS's ROE is -1.53%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, STXS is more volatile compared to NEUE. This indicates higher risk in terms of short-term price fluctuations for STXS.Check NEUE's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while SNWV trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas SNWV's P/E ratio is 17.82. In terms of profitability, STXS's ROE is -1.53%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, STXS is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for STXS.Check SNWV's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while EKSO trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas EKSO's P/E ratio is -3.11. In terms of profitability, STXS's ROE is -1.53%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, STXS is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for STXS.Check EKSO's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while BEAT trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas BEAT's P/E ratio is -0.94. In terms of profitability, STXS's ROE is -1.53%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, STXS is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for STXS.Check BEAT's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while STSSW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas STSSW's P/E ratio is -0.03. In terms of profitability, STXS's ROE is -1.53%, compared to STSSW's ROE of N/A. Regarding short-term risk, STXS is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for STXS.Check STSSW's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas SPAN's P/E ratio is N/A. In terms of profitability, STXS's ROE is -1.53%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, STXS is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for STXS.Check SPAN's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, STXS's ROE is -1.53%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, STXS is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check EXAC's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas ABCO's P/E ratio is 0.52. In terms of profitability, STXS's ROE is -1.53%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, STXS is more volatile compared to ABCO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ABCO's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas SCAI's P/E ratio is 63.45. In terms of profitability, STXS's ROE is -1.53%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, STXS is more volatile compared to SCAI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check SCAI's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, LDR has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas LDR's P/E ratio is N/A. In terms of profitability, STXS's ROE is -1.53%, compared to LDR's ROE of +1.17%. Regarding short-term risk, STXS is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check LDR's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas MZOR's P/E ratio is -70.18. In terms of profitability, STXS's ROE is -1.53%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, STXS is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for STXS.Check MZOR's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas MEDC's P/E ratio is N/A. In terms of profitability, STXS's ROE is -1.53%, compared to MEDC's ROE of N/A. Regarding short-term risk, STXS is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for STXS.Check MEDC's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, STJ has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas STJ's P/E ratio is 34.69. In terms of profitability, STXS's ROE is -1.53%, compared to STJ's ROE of +0.21%. Regarding short-term risk, STXS is more volatile compared to STJ. This indicates higher risk in terms of short-term price fluctuations for STXS.Check STJ's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas LPNT's P/E ratio is 67.44. In terms of profitability, STXS's ROE is -1.53%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, STXS is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for STXS.Check LPNT's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas CYNO's P/E ratio is 105.35. In terms of profitability, STXS's ROE is -1.53%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, STXS is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for STXS.Check CYNO's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, PMC has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas PMC's P/E ratio is 47.95. In terms of profitability, STXS's ROE is -1.53%, compared to PMC's ROE of +0.04%. Regarding short-term risk, STXS is more volatile compared to PMC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check PMC's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas ABAX's P/E ratio is 70.62. In terms of profitability, STXS's ROE is -1.53%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, STXS is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for STXS.Check ABAX's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas EVHC's P/E ratio is -3.20. In terms of profitability, STXS's ROE is -1.53%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, STXS is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check EVHC's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, COTV has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas COTV's P/E ratio is 26.51. In terms of profitability, STXS's ROE is -1.53%, compared to COTV's ROE of +0.14%. Regarding short-term risk, STXS is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for STXS.Check COTV's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas AMSG's P/E ratio is N/A. In terms of profitability, STXS's ROE is -1.53%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, STXS is more volatile compared to AMSG. This indicates higher risk in terms of short-term price fluctuations for STXS.Check AMSG's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas SPNC's P/E ratio is -24.03. In terms of profitability, STXS's ROE is -1.53%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, STXS is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for STXS.Check SPNC's competition here

Stereotaxis, Inc. (AMEX: STXS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STXS stands at 139M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, STXS is priced at $1.42 on the AMEX, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STXS currently has a P/E ratio of -8.35, whereas DSCI's P/E ratio is -0.02. In terms of profitability, STXS's ROE is -1.53%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, STXS is more volatile compared to DSCI. This indicates higher risk in terms of short-term price fluctuations for STXS.Check DSCI's competition here